ClinicalTrials.gg
Active, not recruitingNCT07755930Updated Nov 9, 2026

Marsili Syndrome as a Gateway to Novel Analgesic Targets

An interventional study of Histamine and Cowhage (Mucuna Pruriens) in Marsili Syndrome, sponsored by Aalborg University. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Aalborg University · Not applicable, Interventional, and Basic science

How we know

Updated Nov 9, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Congenital insensitivity to pain (CIP) comprises a group of rare genetic disorders caused by mutations in genes essential for pain sensing in humans. Among these, Marsili syndrome is caused by a dominant point mutation in the transcription factor ZFHX2, and it is characterized by markedly reduced sensitivity to noxious heat, mechanical injury, while other functions remain intact. this project aims to establish the first integrated, system-level characterization of Marsili syndrome by combining human sensory phenotyping with neurophysiological and molecular analyses. The study will be conducted in two sessions of approximately 4 hours each, 24 hours apart from each other

02

Conditions studied

  • Marsili Syndrome
03

In context

Lead sponsor

Aalborg University is the lead sponsor of 183 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men and women aged 18-80 years
  • Marsili syndrome
  • Speak and understand English

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Current regular use of cannabis, opioids, cocaine, amphetamines, MDMA/ecstasy, benzodiazepines, barbiturates, hallucinogens, or other central nervous system-active recreational drugs.
  • Current use of prescription medication that may significantly affect pain perception, itch perception, cortical excitability, or inflammatory responses, including opioids, antiepileptic drugs, antidepressants, antipsychotics, systemic , or medication.
  • Current or previous neurological disease, including epilepsy, stroke, traumatic brain injury, spinal cord injury, multiple sclerosis, Parkinson's disease, or other degenerative neurological disorders.
  • Current or previous severe psychiatric disorder, including major depression, psychosis, bipolar disorder, or severe anxiety disorder.
  • Current or previous musculoskeletal, cardiovascular, pulmonary, inflammatory, , or dermatological disease that may interfere with study procedures or outcome measures.
  • Lack of ability to understand study information, provide , or cooperate with study procedures.
  • Abnormally disrupted sleep during the 24 hours before the experiment.
  • to TMS, including previous epileptic seizure, implanted electronic medical devices, metal implants in the head or jaw, implanted hearing aids, facial metal implants, permanent makeup, or tattoos in the facial area.
  • Inability to pass the Transcranial Magnetic Stimulation Adult Safety Screen.
  • Abnormally disrupted sleep in the 24 hours preceding the experiment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (estimated)

Study arms

  • Experimental
    Marsili group

    Other: Histamine · Other: Cowhage (Mucuna Pruriens) · Drug: Capsaicin 8% Patch · Other: Knee Injections of hypertonic saline · Other: Cold Pressure Test · Other: Computerized Conditioned Pain Modulation (CPM)

Interventions

  • OtherHistamine

    To deliver histamine, standard allergy skin prick test (SPT) lancets are applied

  • OtherCowhage (Mucuna Pruriens)

    The spicules will be manually inserted. Approximately 30-35 spicules are gently rubbed into a 1 cm diameter skin area on the forearm

  • DrugCapsaicinStudies of CapsaicinCapsaicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Capsaicin patches (2x2 cm, dosage form: transdermal patch 8%) will be applied on the selected area. The patch will be left in place for 30 minutes after which it will be removed.

  • OtherKnee Injections of hypertonic saline

    Experimental knee pain will be induced with a 0.25-0.30 mL bolus injection of 5% hypertonic saline, which will be injected into the dominant Infrapatellar Fat Pad (IFP)

  • OtherCold Pressure Test

    Participants will be asked to place their hand in the cold-water tank (temperature around 5°C) and to keep it for as long as they can tolerate it.

  • OtherComputerized Conditioned Pain Modulation (CPM)

    CPM will be assessed using a double-cuff.

06

What researchers measure

Primary outcomes

  1. Measuring pain by computerized Visual Analog Scale Scoring

    We will ask the subjects to rate the sensation of pain on a scale from 0 to100, where 0 represents no pain and 100 represent the worst imaginable pain.

    Time frame: Day 1

  2. Measuring pain by computerized Visual Analog Scale Scoring

    We will ask the subjects to rate the sensation of pain on a scale from 0 to100, where 0 represents no pain and 100 represent the worst imaginable pain.

    Time frame: Day 2

  3. Measuring Itch by computerized Visual Analog Scale Scoring

    We will ask the subjects to rate the sensation of itch on a scale from 0 to100, where 0 represents no itch and 100 represent the worst imaginable itch.

    Time frame: Day 1

  4. Measuring Itch by computerized Visual Analog Scale Scoring

    We will ask the subjects to rate the sensation of itch on a scale from 0 to100, where 0 represents no itch and 100 represent the worst imaginable itch.

    Time frame: Day 2

  5. Alloknesis

    Measured using a standardized sensory brush exerting a force of 200 to 400 mN.

    Time frame: Day 1

  6. Alloknesis

    Measured using a standardized sensory brush exerting a force of 200 to 400 mN.

    Time frame: Day 2

  7. Mechanically evoked itch (MEI)

    MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).

    Time frame: Day 1

  8. Mechanically evoked itch (MEI)

    MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).

    Time frame: Day 2

  9. Mechanical Pain Thresholds (MPT)

    This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN.

    Time frame: Day 1

  10. Mechanical Pain Thresholds (MPT)

    This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN.

    Time frame: Day 2

  11. Mechanical Pain Sensitivity (MPS)

    This test is conducted with the same pinprick set used to test the MPT.

    Time frame: Day 2

  12. Mechanical Pain Sensitivity (MPS)

    This test is conducted with the same pinprick set used to test the MPT.

    Time frame: Day 1

  13. Pressure Pain Threshold

    Pressure pain threshold (PPT) is obtained using a manual pressure algometer

    Time frame: Day 1

  14. Pressure Pain Threshold

    Pressure pain threshold (PPT) is obtained using a manual pressure algometer

    Time frame: Day 2

  15. Mechanical Suprathreshold Pain Stimulation

    Once PPT has been determined, stimuli of 130% of the PPT will be delivered to the limb or shoulder to create a sensation of subjective mild/moderate pain

    Time frame: Day 2

  16. Computerized Cuff Pressure Algometer (CPA)

    A computer-controlled cuff pressure algometer works by inflating a cuff/tourniquet, which is similar in design to those used for measuring blood pressure

    Time frame: Day 1

  17. Spatial and Temporal Summation of Pain

    Spatial and temporal summation of pain will be assessed with the use of the computerized cuff pressure algometer

    Time frame: Day 1

  18. Cold Detection Thresholds (CDT)

    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

    Time frame: Day 1

  19. Cold Detection Thresholds (CDT)

    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

    Time frame: Day 2

  20. Warm Detection Thresholds (WDT)

    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

    Time frame: Day 1

  21. Warm Detection Thresholds (WDT)

    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

    Time frame: Day 2

  22. Cold Pain Thresholds (CPT)

    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

    Time frame: Day 1

  23. Cold Pain Thresholds (CPT)

    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

    Time frame: Day 2

  24. Heat Pain Thresholds (HPT)

    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

    Time frame: Day 1

  25. Heat Pain Thresholds (HPT)

    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

    Time frame: Day 2

  26. Pain to Supra-threshold Heat Stimuli (STHS)

    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

    Time frame: Day 1

  27. Pain to Supra-threshold Heat Stimuli (STHS)

    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device

    Time frame: Day 2

  28. EEG recording

    The EEG signal will be acquired constantly through 64 electrodes placed on the scalp according to the international 10-20 system with a standard EEG cap

    Time frame: Day 1

  29. Measuring cortical responses to magnetic stimulation

    Transcranial magnetic stimulation (TMS) will be used to evoke cortical responses (TMSevoked potentials - TEPs) in the left and right motor cortex with a figure-eight-shaped cone coil (200 pulses for each target).

    Time frame: Day 1

Secondary outcomes

  1. Superficial blood perfusion

    Superficial blood perfusion (SBP) is measured by a Speckle contrast imager

    Time frame: Day 1

  2. Superficial blood perfusion

    Superficial blood perfusion (SBP) is measured by a Speckle contrast imager

    Time frame: Day 2

  3. Pain Catastrophizing Scale (PCS).

    The PCS assesses negative and exaggerated coping concerning anticipated or experienced painful stimuli. Thirteen items have to be answered on a 5-point Likert-type scale ranging from 0 (Not at all) to 4 (all the time).

    Time frame: Baseline

  4. Itch Catastrophizing Scale (ICS).

    The ICS assesses negative and exaggerated coping concerning anticipated or experienced itchy stimuli. Thirteen items have to be answered on a 5-point Likert-type scale ranging from 0 (Not at all) to 4 (all the time).

    Time frame: Baseline

  5. Reinforcement Sensitivity Theory - Personality Questionnaire (RST-PQ).

    The RST-PQ contains in total, 65 items must be answered on a 4-point Likert-type scale

    Time frame: Baseline

  6. Depression, Anxiety, Stress Scale (DASS-21)

    The questionnaire measures the magnitude of depression, anxiety, and stress. Each of these three subscales consists of 7 questions answered using a 0-3 Likert scale, with 0 meaning "it did not apply to me", and 3 meaning "it applied to me very much"

    Time frame: Baseline

  7. Learned Helplessness Scale (LHS)

    The questionnaire consists of 20 items, and the participant's response to each item is rated on a 4-point Likert scale ranging from strongly agree (1) to strongly disagree (4).

    Time frame: Baseline

  8. Positive And Negative Affect Schedule (PANAS)

    Twenty words are associated with the subject's current feelings and have to be rated on a 5-points Likert-type scale, whit 0 corresponding to "not at all" and 5 corresponding to "Very".

    Time frame: Baseline

  9. Difficulties in Emotion Regulation Scale Short Form (DERS-SF)

    The questionnaire is an 18-item measure used to identify emotional regulation issues in adults. Participants rate each item on a 5-point Likert scale (from 1 to 5).

    Time frame: Baseline

  10. Emotion Regulation Questionnaire (ERQ)

    This questionnaire is designed to assess individual differences in the habitual use of two emotion regulation strategies: cognitive reappraisal and expressive suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree), where 4 means (neutral).

    Time frame: Baseline

  11. The Pittsburg Sleep Quality Index (PSQI)

    Consists of seven scored from zero to 21 with higher scores reflecting a worse overall quality o: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.

    Time frame: Baseline

  12. Multidimensional Assessment of Interoceptive Awareness (MAIA-2)

    MAIA-2 consists of 37 self-report items that evaluates multiple dimensions of interoception, distinguishing between simple detection of bodily signals and the cognitive-affective interpretation of those signals.

    Time frame: Baseline

  13. Body Perception Questionnaire (BPQ-SF)

    BPQ-SF consists of 12 self-report items designed to assess the frequency and intensity of perceived autonomic and somatic bodily sensations.

    Time frame: Baseline

  14. The International Physical Activity Questionnaire (IPAQ)

    IPAQ is a standardized self-report instrument developed to assess habitual physical activity levels

    Time frame: Baseline

  15. Mediterranean Diet Adherence Screener (MEDAS)

    MEDAS is a validated 14-point questionnaire to evaluate dietary habits

    Time frame: Baseliene

Other outcomes

  1. Genomic DNA isolation

    Isolation will be performed using a validated commercial kit

    Time frame: Baseline

  2. MicroRNA assessment

    The total circulating miRNA will include the evaluation of circulating markers through targeted Next-Generation Sequencing

    Time frame: Baseline

  3. Proteome assessment

    Quantitative proteome analysis will be performed using mass spectrometry

    Time frame: Baseline

07

Study locations

1 site
  • Center for Neuroplasticity and Pain Faculty of Medicine, Aalborg University Selma Lagerløfs Vej 249 9260 Gistrup, Denmark
    Gistrup, Aalborg 9260, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 10, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Active, not recruiting
    + 2 other changes: date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07755930
Lead sponsor
Aalborg University
Responsible party
Silvia Lo Vecchio (Associate professor, Aalborg University) — Principal investigator
First posted
Aug 10, 2026
Start date
Aug 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capsaicin

Start the discussion